Drug tolerance in bacteria is widely believed to be due to metabolic changes that accompany growth arrest. A study in this issue of Cell reveals a drug tolerance mechanism in replicating mycobacteria that is induced by residence in macrophages and depends on drug efflux.
In the context of tuberculosis (TB), directly observed therapy involves a trained observer watching patients take their TB medications in order to improve adherence and achieve a cure. In this issue of Cell, Adams and Takaki and colleagues (Adams et al., 2011) bring new meaning to the term ''directly observed therapy'' by using transparent zebrafish embryos to study the response of Mycobacterium marinum to antimycobacterial drugs. In doing so, they discover an unsuspected mechanism for the phenomenon of bacterial drug tolerance. Bacterial drug tolerance is less well understood than drug resistance, but both limit the successful treatment of many bacterial infections. Bacterial resistance occurs due to selection of genetically mutant, drug-resistant bacteria, some of which are resistant to multiple drugs and can be difficult or impossible to treat. In contrast, drug-tolerant bacteria, also known as persisters in certain contexts, are phenotypically resistant to antimicrobial drugs yet genetically identical to drug-susceptible bacteria in the same population. The importance of drug tolerance is substantial, as it contributes to treatment failures, allows for the emergence of genetic drug resistance, and necessitates prolonged treatment courses that can be costly, toxic, and difficult for patients to complete. A classic and especially important example of drug tolerance occurs in tuberculosis, whose cure currently requires a minimum of 6 months of multiple antimicrobial drugs.
In many cases, drug tolerance is observed in vitro as a biphasic curve of bacterial killing: upon addition of an active drug, there is a rapid exponential decrease in the number of viable bacteria, followed by a slower decrease with prolonged persistence of viable bacteria. Characterization of the bacteria that remain viable reveals that they retain the drug susceptibility of the original population, yet they have survived in the presence of otherwise lethal concentrations of drug. In one especially well-characterized system, the drug-tolerant persisters are in an arrested growth state (Balaban et al., 2004) due to stochastic fluctuations of expression in a specific bacterial toxinantitoxin pair, in which higher expression of the toxin protein causes growth arrest (Rotem et al., 2010) . It is widely believed that a general property of drug-tolerant bacteria is that they are growing slowly or not at all and that the metabolic changes that accompany growth arrest account for the inability to be killed by standard antimicrobial drugs.
In this issue of Cell (Adams et al., 2011 ), Adams and Takaki and colleagues provide evidence for a new model of drug tolerance in mycobacteria (Figure 1 ). First, they find that drug-tolerant bacteria need not be in a growth-arrested state. By directly observing fluorescent Mycobacterium marinum in transparent zebrafish embryos, they determine that a subpopulation of bacteria continues to replicate at the same time that the majority of bacteria are killed by antimycobacterial drugs. Second, they find that uptake and residence in macrophages provide the signal for induction of drug tolerance. Drugtolerant bacteria were observed very early after infection of zebrafish embryos, but tolerance did not occur in embryos that are deficient in macrophages due to knockdown of the PU.1 transcription factor. In addition, drug tolerance in M. marinum and M. tuberculosis was enhanced by intracellular growth in cultured murine and human macrophages. Of note, the tolerant phenotype was detectable up to 5 days following release from macrophages, indicating that extracellular mycobacteria can exhibit tolerance if they have recently resided within a macrophage. Third, the investigators find that the newly discovered mechanism of tolerance is attributable to bacterial efflux pumps whose expression is induced upon macrophage entry, and at least one of these efflux pumps is essential for optimum mycobacterial survival in macrophages, even in the absence of drug. Inducible drug efflux pumps contribute to drug resistance in many contexts, from multidrug-resistant bacteria to tumor cell resistance to chemotherapy. Indeed, efflux pumps have been implicated in drug-induced drug tolerance in M. tuberculosis. The observation that bacterial efflux pumps can be induced by intracellular localization and contribute to drug tolerance in actively replicating mycobacteria is an especially notable contribution that will surely stimulate further investigation.
The observations reported by Adams and Takaki and colleagues provoke numerous questions. First, what fraction of mycobacterial drug tolerance can be attributed to the macrophage-induced efflux pump mechanism? This is a crucial question, as development of new treatment approaches to TB will depend on the answer. If drug efflux is the major mechanism of tolerance of M. tuberculosis in human infections, then inhibitors of efflux should have a significant treatment-shortening effect, which is currently one of the major goals of TB drug development efforts (Salomon et al., 2006) . On the other hand, if nonreplicating bacteria also make a significant contribution to tolerance, then efforts to develop drugs that target nonreplicating bacteria (Bryk et al., 2008) will also be critical. It will be important to determine whether inhibition of drug efflux shortens the required duration of TB therapy, increases cure rates, or both. Because at least one efflux pump is required for intracellular growth as well as tolerance, targeting such pumps may eradicate infection by dual mechanisms. A practical problem to address is that it appears that distinct pumps are used for efflux of distinct drugs; in particular, Adams and Takaki et al. report that verapamil reduces tolerance to rifampin, but not isoniazid, in M. tuberculosis. Thus, the identification of more efflux pump inhibitors will be needed before it is clear whether treatment of TB can be improved by the addition of a single inhibitor. It will also be important to define the macrophage signals that induce expression of the relevant bacterial efflux pumps and how these signals are received and transduced by mycobacteria. If one signal induces multiple efflux pumps, then targeting that signaling pathway may provide an approach to overcoming tolerance of multiple drugs simultaneously. Finally, is the phenomenon of host induction of drug tolerance a general phenomenon in bacteria, or is it confined to mycobacteria and other intracellular pathogens? Because drug tolerance is observed and prolonged courses of antibiotics are required in other infections, the finding that drug tolerance can occur in populations of replicating mycobacteria should prompt assessment of whether similar principles apply to other infectious diseases. Directly observed therapy for TB infection in humans improves cure rates and reduces the emergence of drug resistance. The insight derived from directly observed therapy in zebrafish has the potential to make a similar contribution. 
